摘要
目的探讨替比夫定联合扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化的临床效果。方法 72例慢性乙型肝炎患者分为研究组和对照组,各36例。对照组给予替比夫定治疗,研究组则给予替比夫定联合扶正化瘀胶囊进行治疗,对比两组患者治疗前后的肝功能、HBV-DNA以及血清肝纤维化指标的变化情况。结果两组患者经治疗后肝功能指标均有所改善,研究组的改善程度明显优于对照组;研究组患者的肝纤维化指标改善亦明显优于对照组(P<0.05),在HBV-DNA转阴情况对比,无显著差异(P>0.05)。结论替比夫定联合扶正化瘀胶囊治疗慢性乙型肝炎抗纤维化效果显著,能有效改善慢性乙肝肝纤维化患者的病情及预后情况,值得在临床上推广应用。
Objective To explore the effect of Telbivudine united the centralizer blood capsule for the treatment of liver fibrosis induced by chronic hepatitis B. Methods 72 patients with chronic hepatitis were divided into the research group and the control group,each group 36 cases. The control group was given Telbivudine,the treatment group was given co-administration of Telbivudine and the centralizer blood capsule. The liver function and HBV-DNA and the change of serum liver fibrosis indexes of two groups of patients were compared before and after treatment. Results The liver function index of two groups were improved after treatment,the improvement of the treatment group was significantly better than the control group. The same trend was observed in the liver fibrosis index（ P〈 0. 05）,but no significant difference were observed between two groups in the HBV-DNA overcast conditions（ P〉 0. 05）. Conclusion The effect of co-administration of Telbivudine and the centralizer blood capsule on anti-fibrosis induced by chronic hepatitis B is significantly,which is worth popularization and application in clinic.
出处
《吉林医药学院学报》
2015年第2期88-90,共3页
Journal of Jilin Medical University
关键词
替比夫定
扶正化瘀胶囊
慢性乙型肝炎
肝纤维化
telbivudine
the centralizer blood capsule
chronic hepatitis b
liver fibrosis
